聯影醫療(688271.SH):2024年度淨利潤12.62億元,同比下降36.08%
格隆匯2月27日丨聯影醫療(688271.SH)公佈2024年度業績快報,公司2024年度實現營業總收入1,030,010.44萬元,同比下降9.73%;實現歸屬於母公司所有者的淨利潤126,186.95萬元,同比下降36.08%;實現歸屬於母公司所有者的扣除非經常性損益的淨利潤101,032.34萬元,同比下降39.32%。
公司在報吿期內,持續增大研發投入,推動科技創新,受國內設備更新政策落地節奏的影響,行業整體規模較上年同期有較大收縮,儘管公司在國內市場佔有率保持領先水平,國內收入仍較上年同期有所下降;同時,公司繼續加強海外市場開拓及創新型產品的導入,實現海外收入的持續較快增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.